Items Tagged ‘Acute Lymphoblastic Leukemia’

September 5th, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy


September 1st, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


September 1st, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


August 22nd, 2017

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

By

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US1. Effective treatment options for patients with r/r […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B-cell, Besponsa, Inotuzumab, Leukemia, News, ozogamicin, targeted therapy


December 14th, 2016

FDA Grants Iclusig® Expanded Approval for CML

By

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, CML, Iclusig, Leukemia, News, PACE trial, Ph+ ALL, ponatinib, TKI, tyrosine kinase inhibitor


September 26th, 2016

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia

By

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the rapid uncontrolled growth of abnormal, […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, CD20-positive, Childhood Acute Lymphoblastic Leukemia, children, Leukemia, News, Ph-negative, Philadelphia chromosome (PH)-negative acute lymphoblastic leukemia


September 6th, 2016

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia

By

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to prior therapy. These results were recently published in the New England Journal of Medicine. Acute lymphoblastic leukemia (ALL) is an aggressive form of leukemia with limited treatment options once it progresses […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, inotuzumab ozogamicin, Leukemia, lymphoblastic leukemia, News


June 23rd, 2016

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia

By

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive […]

View full entry

Tags: 2016, Acute Lymphoblastic Leukemia, all, BCP-ALL, blinatumomab, blincyto, EAH, Leukemia, News, TOWER trial


May 16th, 2016

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia

By

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article in the Journal of Clinical Oncology. Acute lymphoblastic leukemia (ALL) is a fast-growing form of leukemia, and is a common type of […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, children, cortisol, dexamethasone, hydrocortisone, Leukemia, News


January 19th, 2016

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

By

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, acute lymphoblastic lymphoma, all, blincyto, cd19, immunotherapy, Leukemia, News, Philadelphia chromosome positive


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 16th, 2015

Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias

By

The addition of Rituxan (rituximab) to standard chemotherapy-based regimens improves outcomes among patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is CD20-positive. These results were reported at a plenary session at the 2015 annual meeting of the American Society of Hematology in Orlando, Florida. B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is an aggressive type […]

View full entry

Tags: Acute Lymphoblastic Leukemia, B-cell precursor acute lymphoblastic leukemia, BCP-ALL, CD20-positive, Leukemia, News, riruximab, rituxan


July 23rd, 2015

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising

By

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, blincyto, Leukemia, News


May 19th, 2015

Blincyto®

By

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

View full entry

Tags: Acute Lymphoblastic Leukemia, B, Biological Therapy, blincyto, Drug Dictionary


May 19th, 2015

Blinatumomab

By

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B, Biological Therapy, blincyto, Drug Dictionary